NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 10, 2025
NBIX$168.86+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in millions, except per share data) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $233.0 | $251.1 |
| Available-for-sale debt securities | 843.1 | 780.5 |
| Accounts receivable | 479.1 | 439.3 |
| Inventory | 57.4 | 38.3 |
| Other current assets | 112.1 | 97.8 |
| Total current assets | 1,724.7 | 1,607.0 |
| Deferred tax assets | 485.7 | 362.6 |
| Available-for-sale debt securities | 739.5 | 687.5 |
| Right-of-use assets | 509.4 | 276.5 |
| Equity investments | 124.8 | 161.9 |
| Property and equipment, net | 82.6 | 70.8 |
| Intangible assets, net | 36.5 | 35.5 |
| Other noncurrent assets | 15.5 | 49.6 |
| Total assets | $3,718.7 | $3,251.4 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $461.6 | $448.8 |
| Convertible senior notes | — | 170.1 |
| Other current liabilities | 46.1 | 35.9 |
| Total current liabilities | 507.7 | 654.8 |
| Noncurrent operating lease liabilities | 455.1 | 258.3 |
| Other noncurrent liabilities | 166.2 | 106.3 |
| Total liabilities | 1,129.0 | 1,019.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 99.4 and 98.7 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,554.6 | 2,382.0 |
| Accumulated other comprehensive income | 5.8 | 7.0 |
| Retained earnings (accumulated deficit) | 29.2 | (157.1) |
| Total stockholders’ equity | 2,589.7 | 2,232.0 |
| Total liabilities and stockholders’ equity | $3,718.7 | $3,251.4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.